[Latest] Global Cell and Gene Therapy Market Size/Share Worth USD 118.63 Billion by 2034 at a 18.79% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, June 25, 2025 (GLOBE NEWSWIRE) — Custom Market Insights has published a new research report titled “Cell and Gene Therapy Market Size, Trends and Insights By Therapy Type (Cell Theray, Gene Therapy), By Therapeutic Class (Cardiovascular Disease, Cancer, Genetic Disorder, Rare Diseases, Oncology, Hematology, Ophthalmology, Infectious Disease, Neurological Disorders, Others), By Delivery Method (In Vivo, Ex Vivo), By End-User (Hospitals, Cancer Care Centers, Others), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034“ in its research database.

“According to the latest research study, the demand of global Cell and Gene Therapy Market size & share was valued at approximately USD 21.23 Billion in 2024 and is expected to reach USD 25.20 Billion in 2025 and is expected to reach a value of around USD 118.63 Billion by 2034, at a compound annual growth rate (CAGR) of about 18.79% during the forecast period 2025 to 2034.”

Click Here to Access a Free Sample Report of the Global Cell and Gene Therapy Market @ https://www.custommarketinsights.com/request-for-free-sample/?reportid=70573

Overview

According to industry experts at CMI, the implementation of new strategies and technologies by the manufacturers presents lucrative opportunities for players in the Cell and Gene Therapy Market during the forecast period. Furthermore, we expect the growing significance of organized retailing to drive the future growth of the market.

Key Trends & Drivers

• Advancements in Gene Editing Technologies: The development of precise gene editing tools such as CRISPR-Cas9, TALENs, and zinc finger nucleases is reshaping the gene therapy market. These technologies help in the accurate fixing of mutations in the genetic material, along with reducing off-target effects and enhancing safety. We expect CRISPR to gain popularity due to its efficiency, cost-effectiveness, and versatility in treating various genetic disorders. With the evolution of these tools, more clinical programs are now involved in integrating them, including therapies for inherited diseases and certain cancers. Continuous innovations in editing precision, delivery systems, and regulatory oversight are catapulting gene editing to the forefront of gene therapy applications in the future and expanding its commercial scope.

• Gene therapy: is rapidly expanding into rare and orphan diseases, many of which lack established treatments. These conditions often tend to have a well-defined genetic cause, making them apt candidates for gene intervention. Regulatory incentives such as orphan drug designations, priority review, and extended marketing exclusivity provide more encouragement for development in this arena. Emerging therapies are targeting spinal muscular atrophy, Duchenne muscular dystrophy, and inherited retinal disorders, while inroads made by their success have contributed to the further increase in research. This trend is addressing several pressing unmet medical needs while also providing for quicker entry into the marketplace with comparatively less competition, thereby fueling the rapid growth of the gene therapy sector.

• Increasing Regulatory Support and Fast-Track Approvals: Increasingly, worldwide regulatory bodies such as the FDA and EMA are bestowing fast-track designations, breakthrough therapy statuses, and conditional approvals for promising gene therapies. These pathways are meant to fast-track development and review of treatments for serious or life-threatening illnesses. Such a regulatory change indicates growing confidence in gene therapy regarding safety and efficacy, as well as the urgency of putting new treatment modalities on the market. With more therapies entering the clinical success phase, regulatory agencies are now actively working with developers to update and revise the guidance on manufacturing, trial design, and post-market surveillance. Hence, a forward regulatory approach accelerates approvals and enhances investor confidence in the field.

• Growth in Strategic Partnerships and M&A Activity: The gene therapy market is currently witnessing an increase in strategic collaborations, licensing deals, mergers, and acquisitions between biotech startups and large pharma companies. The partnerships then translate into the commercialization of innovation by bringing together innovative research and development with the regulatory, manufacturing, and distribution capabilities of big pharma. The big players are essentially looking to pump life into their pipeline while the smaller players are getting capital infusion and technical know-how. The notable M&A activities give a similar indication of confidence in the long-term value of gene therapies. Therefore, it promotes the efficiency of R&D, speeds up the arrival of products to the market, and shapes a competitive landscape, which in turn helps drive the growth of the market and increase the availability of new proposed treatments.

Request a Customized Copy of the Cell and Gene Therapy Market Report @ https://www.custommarketinsights.com/request-for-customization/?reportid=70573

• Innovations in Delivery Mechanisms: The successful gene therapy needs the efficient delivery of the genetic materials inside the target cells. The innovations in the delivery systems, like adeno-associated viruses, lentiviral vectors, lipid nanoparticles, and non-viral systems are ushering in better therapeutic outcomes and have fewer side effects. These delivery systems are being fine-tuned for specific tissues and diseases, thereby increasing precision while reducing immune responses to the vector. Better platforms also consider vector re-dosing, increased tissue distribution, and efficacy, along with more straightforward manufacturing. As we develop better delivery technologies, the newer ones can treat more types of conditions and keep patients safer, making it easier to use gene therapy widely and helping it gain acceptance in clinics.

• Increasing Investment and Funding Activities: As there has been a surge in the venture capital, private equity, and public market investments coming into the fold, gene therapy is becoming more promising for the research and commercialization. The existence of several high-profile IPOs, funding rounds, and government grants serves as proof of investor confidence in gene therapy and in its ability to bring about a kind of transformation. The finances allow companies to further investigate the R&D, conduct clinical trials, and upgrade manufacturing facilities. Furthermore, there are also public and philanthropic organizations supporting early-stage innovations. This source of funding empowers developers to explore a broader range of diseases, invest in innovative technologies, and aim for global market penetration. Continued funding is a requisite to keep the momentum going and to ensure the long-term sustainability of the gene therapy sector.

Report Scope